NCT03641313 2026-04-13
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
Baylor College of Medicine
Baylor College of Medicine
Baylor College of Medicine
National Cancer Institute (NCI)
Xijing Hospital of Digestive Diseases
Jagiellonian University
Chinese University of Hong Kong
Samsung Medical Center
AdventHealth
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School